share_log

海通国际4月10日发布研报称，给予国药股份（600511.SH）优于大市评级，目标价格为47.60元。评级理由主要包括：1）2023年收入增长9.23%，归母净利润增长9.26%；2）北京地区直销业务稳健增长，市场地位持续领先；3）全国分销业务保持增长，工业板块经营质量提升；4）麻精药分销龙头地位稳固，联营企业利润贡献稳健。（每日经济新闻）

Haitong International released a research report on April 10 stating that Sinopharm shares (600511.SH) were given an superior market rating, and the target price was 47.60 yuan. The main reasons for the rating include: 1) revenue growth of 9.23% in 2023,

Zhitong Finance ·  Apr 11 07:34
Haitong International released a research report on April 10 stating that Sinopharm shares (600511.SH) were given an superior market rating, and the target price was 47.60 yuan. The main reasons for the rating include: 1) revenue growth of 9.23% in 2023, and net profit growth of 9.26%; 2) the direct sales business in Beijing grew steadily, and the market position continued to lead; 3) the national distribution business continued to grow and the quality of operation in the industrial sector improved; 4) the leading position in the distribution of hemp essence drugs was stable, and the profit contribution of joint ventures was steady. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment